SEAnews 2013/cat#22-1p 製薬/生物
左予備スペース
SEAnews SEA Research, BLK 758 Yishun Street 72 #09-444 Singapore 760758
India Front Line Report
右予備スペース
Site Search
Delivered from Singapore
SEAnews Issue:monthly
tel:65-87221054
製薬/生物 Pharma/Biology in 2013
◄◄◄ back18件の関連記事が見つかりました( 1/1 pageを表示 [ 1~18 ] )next ►►►
元のページへ戻る ►2013-08-08 ArtNo.44546(1/18)
◆ランバクシー時価総額3279クロー・アップ
【ムンバイ】地場大手製薬会社Ranbaxy Laboratories Ltd(RLL)の6月期四半期の業績改善に伴い少なからぬ証券会社がその評価を上方修正する中、同社株価は8日28%近い上昇を見た。(...続きを読む)
◆Ranbaxy Laboratories extends rally, m-cap rises by Rs 3,279 cr
Mumbai, Aug 8: Shares of drug major Ranbaxy Laboratories on Thursday surged nearly 28 per cent, after several brokerages upgraded the company following its June quarter performance.
◆兰伯西实验室市值增加3,279 CR卢比
【孟买】多家证券行根据6月季度的表现对该公司评价升级后,主要药物制造商兰伯西实验室的股价8月8日急升近28%。
2013-08-08 ArtNo.44547(2/18)
◆兰伯西实验室市值增加3,279 CR卢比
【孟买】多家证券行根据6月季度的表现对该公司评价升级后,主要药物制造商兰伯西实验室的股价8月8日急升近28%。(...続きを読む)
◆Ranbaxy Laboratories extends rally, m-cap rises by Rs 3,279 cr
Mumbai, Aug 8: Shares of drug major Ranbaxy Laboratories on Thursday surged nearly 28 per cent, after several brokerages upgraded the company following its June quarter performance.
2013-08-08 ArtNo.44548(3/18)
◆Ranbaxy Laboratories extends rally, m-cap rises by Rs 3,279 cr
Mumbai, Aug 8: Shares of drug major Ranbaxy Laboratories on Thursday surged nearly 28 per cent, after several brokerages upgraded the company following its June quarter performance. (...続きを読む)
◆兰伯西实验室市值增加3,279 CR卢比
【孟买】多家证券行根据6月季度的表现对该公司评价升级后,主要药物制造商兰伯西实验室的股价8月8日急升近28%。
2013-08-16 ArtNo.44588(4/18)
◆ジュビラント・ライフ、2013年末までに抗癌剤臨床試験目指す
 Jubilant Life Sciences Ltd(JLSL)は7日、今年末までに米国において新前立腺癌治療薬の臨床試験を行うと発表した。(...続きを読む)
◆Jubilant Life sees cancer drug trials by end-2013
Jubilant Life Sciences Limited said late on Wednesday its new drug aimed at treating prostate cancer is expected to enter clinical trials by the end of this year in the United States.
◆吉友联生命到今年底前开始前列腺癌新药的临床试验
  印度吉友联生命科学有限公司8月7日发表说“其旨在治疗前列腺癌的新药预计到今年年底前在美国进入临床试验。”
2013-08-16 ArtNo.44591(5/18)
◆社説:ワクチン接種政策
 産業省は、外国の医薬品会社が既存の地場製薬会社を買収すること(いわゆるブルウン・フィールド企業買収)にする政策方針を依然として立案していないが、この種の企業買収を認めないと言う主張は日増しに弱々しくなっている。(...続きを読む)
◆Editorial: Vaccinating policy
While the industry ministry is yet to come up with a final policy on whether foreign pharmaceuticals firms are to be allowed to buy existing pharmaceutical producers (brownfield acquisition, in jargon), the case for not doing so is getting weaker by the day—and, by continuing to defer the $1.6 billion takeover of Strides Arcolab’s injectables unit by the US Mylan, the FIPB is sending out the wrong signal to potential investors waiting to bring in money into the country.
◆社论:疫苗接种政策
  虽然工业部还没有拿出最终答案,关于外国制药公司是否获准购买现有医药生产商,事到如今,不这样做的根据越来越弱。
2013-08-16 ArtNo.44589(6/18)
◆吉友联生命到今年底前开始前列腺癌新药的临床试验
  印度吉友联生命科学有限公司8月7日发表说“其旨在治疗前列腺癌的新药预计到今年年底前在美国进入临床试验。”(...続きを読む)
◆Jubilant Life sees cancer drug trials by end-2013
Jubilant Life Sciences Limited said late on Wednesday its new drug aimed at treating prostate cancer is expected to enter clinical trials by the end of this year in the United States.
2013-08-16 ArtNo.44592(7/18)
◆社论:疫苗接种政策
  虽然工业部还没有拿出最终答案,关于外国制药公司是否获准购买现有医药生产商,事到如今,不这样做的根据越来越弱。(...続きを読む)
◆Editorial: Vaccinating policy
While the industry ministry is yet to come up with a final policy on whether foreign pharmaceuticals firms are to be allowed to buy existing pharmaceutical producers (brownfield acquisition, in jargon), the case for not doing so is getting weaker by the day—and, by continuing to defer the $1.6 billion takeover of Strides Arcolab’s injectables unit by the US Mylan, the FIPB is sending out the wrong signal to potential investors waiting to bring in money into the country.
2013-08-16 ArtNo.44590(8/18)
◆Jubilant Life sees cancer drug trials by end-2013
Jubilant Life Sciences Limited said late on Wednesday its new drug aimed at treating prostate cancer is expected to enter clinical trials by the end of this year in the United States.(...続きを読む)
◆吉友联生命到今年底前开始前列腺癌新药的临床试验
  印度吉友联生命科学有限公司8月7日发表说“其旨在治疗前列腺癌的新药预计到今年年底前在美国进入临床试验。”
2013-08-16 ArtNo.44593(9/18)
◆Editorial: Vaccinating policy
While the industry ministry is yet to come up with a final policy on whether foreign pharmaceuticals firms are to be allowed to buy existing pharmaceutical producers (brownfield acquisition, in jargon), the case for not doing so is getting weaker by the day—and, by continuing to defer the $1.6 billion takeover of Strides Arcolab’s injectables unit by the US Mylan, the FIPB is sending out the wrong signal to potential investors waiting to bring in money into the country.(...続きを読む)
◆社论:疫苗接种政策
  虽然工业部还没有拿出最终答案,关于外国制药公司是否获准购买现有医药生产商,事到如今,不这样做的根据越来越弱。
2013-12-20 ArtNo.44660(10/18)
◆トレント·ファーマ、エルダーの国内ビジネスをRs 200億で買収
【ムンバイ】多額の負債に悩む地場製薬会社Elder Pharmaceuticals Ltd(EPL)は、国内およびネパールのブランド製剤ビジネスをグジャラート州Ahmedabad拠点のTorrent Pharmaceuticals Ltd (TPL:BSE -4.04 %)に200億4000万ルピーで売却することに同意、両社は確定契約(definitive agreement)を取り交わした。(...続きを読む)
2013-12-20 ArtNo.44661(11/18)
◆托伦特制药以200亿卢比收购埃尔德制药的制剂业务
【孟买】债务缠身的埃尔德制药公司同意把在印度国内和尼泊尔的品牌制剂业务以200亿4000万卢比向托伦特制药公司出售。两家公司已经签订有关确定合约。(...続きを読む)
2013-12-20 ArtNo.44662(12/18)
◆Torrent Pharma to buy Elder's India business for Rs 2,000 cr
【MUMBAI】Debt-ridden Elder Pharmaceuticals has agreed to sell its branded domestic formulations business in India and Nepal to Ahmedabad-based Torrent Pharmaceuticals for Rs 2,004 crore. The two companies have entered into a definitive agreement.(...続きを読む)
2013-12-20 ArtNo.44663(13/18)
◆エイズ薬アタザナビル後発品の製造が可能に
【ムンバイ】インドの製薬会社は、エイズ薬アタザナビル(atazanavir)の製造に強い関心を抱いて来たが、このほど、多国籍製薬会社Bristol-Myers Squibb (BMS)と国連の支援を受ける医薬品特許プールMPP:Medicines Patent Pool)がライセンス契約を結んだことにより、望みがかないそうだ。(...続きを読む)
2013-12-20 ArtNo.44664(14/18)
◆仿制药业的喜讯,布里斯托尔-迈尔斯签署爱滋病药协定
【孟买】长久以来希望制造爱滋病药阿扎那韦化合物的印度制药公司,托跨国制药公司布里斯托尔-迈尔斯施贵宝公司和联合国支持的药品专利池组织签署协议的福,现在可以实现这项梦。(...続きを読む)
2013-12-20 ArtNo.44665(15/18)
◆Generic possibilities from Bristol-Myers AIDS drug pact
【Mumbai】Indian drug-makers wanting to make AIDS drug atazanavir will now be able to do so, following a licensing agreement signed by multinational pharma firm Bristol-Myers Squibb (BMS) and UN-backed Medicines Patent Pool (MPP). Atazanavir, marketed by BMS under the Reyataz brand, is used in the second-line treatment of HIV/AIDS.(...続きを読む)
2013-12-24 ArtNo.44681(16/18)
◆第一、ランバクシーの米国FDA規則クリア支援
【ニューデリー】第一三共株式会社は、Ranbaxy Laboratories Ltd(RLL)が米国食品薬品局(FDA:Food and Drug Administration)の規則を満たし、禁輸解除を支援する方針を明らかにした。(...続きを読む)
2013-12-24 ArtNo.44682(17/18)
◆日本制药商第一帮助兰伯西符合美国FDA标准
【新德里】日本制药商第一三共公司已经表示,它将帮助兰伯西实验室有限公司符合美国美国食品药品管理局(FDA)的标准并脱离FDA制裁。(...続きを読む)
2013-12-24 ArtNo.44683(18/18)
◆Daiichi to help Ranbaxy meet US FDA norms
【New Delhi】Japanese drug-maker Daiichi Sankyo has said it will help Ranbaxy Laboratories Ltd meet the US Food and Drug Administration's (FDA) norms to overcome sanctions.(...続きを読む)
右ペイン・広告スペース
[Your Comments / Unsubscribe]/[您的意见/退订]/[ご意見/配信停止]
Please do not directly reply to the e-mail address which is used for delivering the newsletter.
请别用递送新闻的邮件地址而直接回信。
メールをお届けした送信専用アドレスには返信しないで下さい。
SEAnews 掲載記事の無断転載を禁じます。すべての内容は日本の著作権法並びに国際条約により保護されています。
Copyright 2003 SEAnews® All rights reserved. No reproduction or republication without written permission.